SCHEMBL5537487

SCHEMBL5537487

[O]c1ccc(N2CCC(Nc3ccccc3OC(F)(F)F)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 1/20 0.46
CRBN Q96SW2 1/20 0.46
EPHX2 P34913 1/20 0.40
CHRM4 P08173 6/20 0.40
SCD O00767 1/20 0.38
SSTR1 P30872 1/20 0.38
SSTR4 P31391 1/20 0.38
CASR P41180 2/20 0.37
S1PR1 P21453 1/20 0.37
CHRM1 P11229 1/20 0.37
DRD2 P14416 1/20 0.36
GAA P10253 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
EGFR P00533 1/20 0.36
BTK Q06187 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539021 0.91 SCD (0.37) DDB1CRBNEPHX2CHRM4SCD
SCHEMBL5537491 0.88 ME3 (0.44) DDB1CRBNEPHX2CHRM4SCD
SCHEMBL5544169 0.84 DRD2 (0.51) DRD2GAAEGFR
SCHEMBL5544308 0.81 SCD (0.57) EPHX2SCDGAA
SCHEMBL5535582 0.79 GAA (0.53) EPHX2SCDGAA
SCHEMBL5541081 0.79 SCD (0.46) EPHX2CHRM4SCDGAA
SCHEMBL5542569 0.79 NOTUM (0.46) CHRM4CASR
SCHEMBL5539025 0.79 ME3 (0.43) DDB1CRBNCHRM4SCDGAA
SCHEMBL5544277 0.78 EPHX2 (0.46) EPHX2CHRM4CASR
SCHEMBL5536338 0.77 KMT2A (0.49) EPHX2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 DDB1 524/4885CRBN 2133/4885EPHX2 3662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.